Careers     Contact     中文  |  English

News and events

AmadorBio 1st anniversary celebration

Amador Bioscience was founded in 2018,at the very beginning,only consists of four partners with global industry experience and profound academic background.            

After one year's efforts and business expansion, Amador team has been growing rapidly, exceeding its revenue targets, successfully exploring customer channels and becoming partners of many companies with small & medium-sized innovative biotechnology corporations with ivy league universities and wall-street background to large multinational biopharma. 

Amador has bio-hubs in the Bay Area of San Francisco, USA and Hangzhou, China. In 2019, we will continue to expand the scale of our laboratories as business and projects increasing.           

In the future, Amador will continue to set sailing, continue to uphold the concept of senior academic background and industrial experience, trans-Pacific resource allocation, excellent operation, and provide more excellent professional services for domestic and multinational customers in clinical development stages of biomedicine.

 

We welcomed a new scientist to AmadorBio

It’s a great pleasure to have Dr. Ryan Criste join Amador Consulting Sector (USA) as Director of Clinical Pharmacology on Monday, March 18. 

Ryan obtained his Doctor of Pharmacy (PharmD) degree from Duquesne University (Pittsburgh, Pennsylvania) in 2006. He further received clinical and PKPD postdoc trainings at Allegheny General Hospital and School of Pharmacy, University of North Carolina before joining the industry, initially at Quantiles and then MedImmune/AstraZeneca.  During his tenure at MedImmune (2009-2013) Ryan was involved in essentially all the clinical projects supported by the clin pharm group at the company headquarters in Gaithersburg, Maryland. Ryan spent the past 5+ years working as senior/lead pharmacokineticist at PPD, providing integrated biopharmaceutical consulting services and clinical development reports in a format suitable for submission to the US FDA. This time he rejoined Amador from Altria, where he was a principal scientist and regulatory study lead for clinical services. Many of Amador team who previously worked at MedImmune/AstraZeneca know Ryan well; it is our great pleasure to have him back. In addition to the biopharma experience, Ryan holds the pharmacy licensure in North Carolina and Pennsylvania.

With Ryan‘s expertise and experience,AmadorBio Team will be stronger and growing rapidly!

 

Amador First Forum

Amador Forum I – fulfilled perfectly

In order to help pharmaceutical companies develop innovative drugs more scientifically, effectively and normatively,introduce Advanced Bioassay Technology and Clinical Trial Ideas and Regulations,contribute to the improvement of China's new drug R&D industry chain,AmadorBio has determined to launch“ Amadorbio series forum. AmadorBio collaborated with Precision Medicine (Hangzhou) Research Center to hold “AmadorBio Forum I”, which has attracted numerous nationwide enterprises participating in this forum, and the site was fully seated.

For the sake of known by more companies, Amador held the activity of “ Entering into Amador” on 19-20 Jan 2019, we have invited the leaders and heads of departments of AstraZeneca, CBMG,Shijian Biology and Kira etc. to visit AmadorBio  Analysis Laboratory in Hangzhou.  

Under the guidance of Dr. Wang Bing (CEO of AmadorBio), Dr. Zeng Rong (COO) and Chen Xiaomin (GM), the delegation visited fully permeable clean experimental lab areas of  AmadorBio by Wearing goggles, isolation clothes, listening with interest to Dr. Zeng's explanation on the division of responsibilities in different areas of the laboratory.   

After visiting the laboratory area, the business development from biological analysis to clinical management was introduced to the attendees, who have made enquiries to the speakers one after another. The atmosphere was relaxed and active. 

This activity made the visiting enterprises know more about the current laboratory construction of AmadorBio and the planned business projects, also offered AmadorBio some opinions and suggestions, which provided valuable experience for the further development of the laboratory.